HEPATITIS-A VIRAL SAFETY OF PLASMA-DERIVED FACTOR-VIII CONCENTRATE KOATE(R)-HP

被引：3
|
作者：
MITRA, G
DOBKIN, M
DUMAS, M
NG, P
ROLDAN, G
GALLOWAY, C
机构：
来源：
VOX SANGUINIS | 1994年 / 67卷
关键词：
D O I：
10.1111/j.1423-0410.1994.tb00985.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：80 / 82
页数：3
相关论文
共 50 条
  • [21] Clinical Efficacy and Safety of Fanhdi (R), a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study
    Jimenez-Yuste, Victor
    Alvarez-Roman, Maria Teresa
    Bravo, Angeles Palomo
    Galmes, Bernardo J.
    Hernandez, Maria del Mar Nieto
    Hidalgo, Olga Benitez
    Alonso, Cristina Marzo
    Gonzalez, Noelia Florencia Perez
    Coll, Julia
    Nunez, Ramiro
    Carrasco, Marina
    Candel, Faustino Garcia
    Gonzalez-Porras, Jose Ramon
    Garcia, Carmen Hernandez
    Castro, Maria Jose Varo
    Mir, Roser
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [22] Why plasma-derived factor VIII?
    Aledort, Louis
    Carpenter, Shannon L.
    Cuker, Adam
    Kulkarni, Roshni
    Recht, Michael
    Young, Guy
    Leissinger, Cindy
    HAEMOPHILIA, 2019, 25 (03) : E183 - E185
  • [23] Derivation of a Pharmacokinetic Model to Include a Plasma-Derived, von Willebrand Factor-Containing Factor VIII (Koate®-DVI) Concentrate and its Low-Dose Use
    Hajducek, Dagmar M.
    Primacakti, Fitri
    Chozie, Novie
    Mir, Roser
    McEneny-King, Alanna
    Iorio, Alfonso
    Edginto, Andrea
    PLASMATOLOGY, 2021, 15
  • [24] Characterization of a plasma-derived double-viral-inactivated factor VIII concentrate (antihaemophilic factor [human]): Focus on TTP treatment
    Mori, Filippo
    Nardini, Ilaria
    Caricasole, Andrea
    Amega, Novinyo Serge
    Farina, Claudio
    HAEMOPHILIA, 2021, 27 (03) : E409 - E411
  • [25] ECONOMIC IMPACT OF TREATING SEVERE HEMOPHILIA A PATIENTS WITH PLASMA-DERIVED FACTOR-VIII/VWF VERSUS RECOMBINANT FACTOR-VIII IN THE UNITED STATES
    O'Day, K.
    Runken, M. C.
    Meyer, K. L.
    Spears, J. B.
    VALUE IN HEALTH, 2017, 20 (05) : A216 - A217
  • [26] A Systematic Review of Efficacy and Safety of Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Voncento) in von Willebrand Disease
    Rugeri, Lucia
    Thomas, Will
    Schirner, Kathrin
    Heyder, Lisa
    Auerswald, Guenter
    THROMBOSIS AND HAEMOSTASIS, 2024, 124 (09) : 828 - 841
  • [27] ALUMINUM HYDROXIDE ABSORPTION OF FACTOR-VIII PROCOAGULANT ANTIGEN FROM PLASMA AND FACTOR-VIII CONCENTRATE
    KEMBALLCOOK, G
    FURLONG, RA
    PEAKE, IR
    BARROWCLIFFE, TW
    THROMBOSIS RESEARCH, 1981, 23 (1-2) : 193 - 196
  • [28] Rituximab and Intermediate-Purity Plasma-Derived Factor VIII Concentrate (Koate®) as Adjuncts to Therapeutic Plasma Exchange For Thrombotic Thrombocytopenic Purpura in Patients With an ADAMTS13 Inhibitor
    Pandey, Soumya
    Nakagawa, Mayumi
    Rosenbaum, Eric R.
    Arnaoutakis, Konstantinos
    Hutchins, Laura F.
    Makhoul, Issam
    Milojkovic, Natasha
    Cottler-Fox, Michele
    JOURNAL OF CLINICAL APHERESIS, 2015, 30 (01) : 50 - 54
  • [29] TRANSMISSION OF HUMAN PARVOVIRUS B19 BY PLASMA-DERIVED FACTOR-VIII CONCENTRATES
    LAURIAN, Y
    DUSSAIX, E
    PARQUET, A
    CHALVONDEMERSAY, A
    DOIRON, R
    TCHERNIA, G
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1994, 36 (06): : 449 - 453
  • [30] HEPATITIS-A VIRUS-INFECTION - NO CONCLUSIVE LINK TO FACTOR-VIII
    PROWSE, C
    BRITISH MEDICAL JOURNAL, 1993, 307 (6903): : 561 - 562
12345